BioStock: Merger strengthens Toleranzia’s prospects

Toleranzia and its major shareholder Flerie are proposing a merger, with Toleranzia’s assets living on in an unlisted environment. The merger will improve the ability to finance the continued development of Toleranzia’s drug projects while providing shareholders with a more risk-balanced exposure to Flerie’s broad portfolio. BioStock contacted Charlotte Fribert, CEO of Toleranzia, and Ted Fjällman, CEO of Flerie, to learn more about the deal.

Read the full article at biostock.se:

https://www.biostock.se/en/2025/03/merger-strengthens-toleranzias-prospects/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se